Cargando…

Additive value of [(18)F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome

PURPOSE: Early after [(18)F]PI-2620 PET tracer administration, perfusion imaging has potential for regional assessment of neuronal injury in neurodegenerative diseases. This is while standard late-phase [(18)F]PI-2620 tau-PET is able to discriminate the 4-repeat tauopathies progressive supranuclear...

Descripción completa

Detalles Bibliográficos
Autores principales: Katzdobler, Sabrina, Nitschmann, Alexander, Barthel, Henryk, Bischof, Gerard, Beyer, Leonie, Marek, Ken, Song, Mengmeng, Wagemann, Olivia, Palleis, Carla, Weidinger, Endy, Nack, Anne, Fietzek, Urban, Kurz, Carolin, Häckert, Jan, Stapf, Theresa, Ferschmann, Christian, Scheifele, Maximilian, Eckenweber, Florian, Biechele, Gloria, Franzmeier, Nicolai, Dewenter, Anna, Schönecker, Sonja, Saur, Dorothee, Schroeter, Matthias L., Rumpf, Jost-Julian, Rullmann, Michael, Schildan, Andreas, Patt, Marianne, Stephens, Andrew W., van Eimeren, Thilo, Neumaier, Bernd, Drzezga, Alexander, Danek, Adrian, Classen, Joseph, Bürger, Katharina, Janowitz, Daniel, Rauchmann, Boris-Stephan, Stöcklein, Sophia, Perneczky, Robert, Schöberl, Florian, Zwergal, Andreas, Höglinger, Günter U., Bartenstein, Peter, Villemagne, Victor, Seibyl, John, Sabri, Osama, Levin, Johannes, Brendel, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816230/
https://www.ncbi.nlm.nih.gov/pubmed/36102964
http://dx.doi.org/10.1007/s00259-022-05964-w
_version_ 1784864486258114560
author Katzdobler, Sabrina
Nitschmann, Alexander
Barthel, Henryk
Bischof, Gerard
Beyer, Leonie
Marek, Ken
Song, Mengmeng
Wagemann, Olivia
Palleis, Carla
Weidinger, Endy
Nack, Anne
Fietzek, Urban
Kurz, Carolin
Häckert, Jan
Stapf, Theresa
Ferschmann, Christian
Scheifele, Maximilian
Eckenweber, Florian
Biechele, Gloria
Franzmeier, Nicolai
Dewenter, Anna
Schönecker, Sonja
Saur, Dorothee
Schroeter, Matthias L.
Rumpf, Jost-Julian
Rullmann, Michael
Schildan, Andreas
Patt, Marianne
Stephens, Andrew W.
van Eimeren, Thilo
Neumaier, Bernd
Drzezga, Alexander
Danek, Adrian
Classen, Joseph
Bürger, Katharina
Janowitz, Daniel
Rauchmann, Boris-Stephan
Stöcklein, Sophia
Perneczky, Robert
Schöberl, Florian
Zwergal, Andreas
Höglinger, Günter U.
Bartenstein, Peter
Villemagne, Victor
Seibyl, John
Sabri, Osama
Levin, Johannes
Brendel, Matthias
author_facet Katzdobler, Sabrina
Nitschmann, Alexander
Barthel, Henryk
Bischof, Gerard
Beyer, Leonie
Marek, Ken
Song, Mengmeng
Wagemann, Olivia
Palleis, Carla
Weidinger, Endy
Nack, Anne
Fietzek, Urban
Kurz, Carolin
Häckert, Jan
Stapf, Theresa
Ferschmann, Christian
Scheifele, Maximilian
Eckenweber, Florian
Biechele, Gloria
Franzmeier, Nicolai
Dewenter, Anna
Schönecker, Sonja
Saur, Dorothee
Schroeter, Matthias L.
Rumpf, Jost-Julian
Rullmann, Michael
Schildan, Andreas
Patt, Marianne
Stephens, Andrew W.
van Eimeren, Thilo
Neumaier, Bernd
Drzezga, Alexander
Danek, Adrian
Classen, Joseph
Bürger, Katharina
Janowitz, Daniel
Rauchmann, Boris-Stephan
Stöcklein, Sophia
Perneczky, Robert
Schöberl, Florian
Zwergal, Andreas
Höglinger, Günter U.
Bartenstein, Peter
Villemagne, Victor
Seibyl, John
Sabri, Osama
Levin, Johannes
Brendel, Matthias
author_sort Katzdobler, Sabrina
collection PubMed
description PURPOSE: Early after [(18)F]PI-2620 PET tracer administration, perfusion imaging has potential for regional assessment of neuronal injury in neurodegenerative diseases. This is while standard late-phase [(18)F]PI-2620 tau-PET is able to discriminate the 4-repeat tauopathies progressive supranuclear palsy and corticobasal syndrome (4RTs) from disease controls and healthy controls. Here, we investigated whether early-phase [(18)F]PI-2620 PET has an additive value for biomarker based evaluation of 4RTs. METHODS: Seventy-eight patients with 4RTs (71 ± 7 years, 39 female), 79 patients with other neurodegenerative diseases (67 ± 12 years, 35 female) and twelve age-matched controls (69 ± 8 years, 8 female) underwent dynamic (0–60 min) [(18)F]PI-2620 PET imaging. Regional perfusion (0.5–2.5 min p.i.) and tau load (20–40 min p.i.) were measured in 246 predefined brain regions [standardized-uptake-value ratios (SUVr), cerebellar reference]. Regional SUVr were compared between 4RTs and controls by an ANOVA including false-discovery-rate (FDR, p < 0.01) correction. Hypoperfusion in resulting 4RT target regions was evaluated at the patient level in all patients (mean value − 2SD threshold). Additionally, perfusion and tau pattern expression levels were explored regarding their potential discriminatory value of 4RTs against other neurodegenerative disorders, including validation in an independent external dataset (n = 37), and correlated with clinical severity in 4RTs (PSP rating scale, MoCA, activities of daily living). RESULTS: Patients with 4RTs had significant hypoperfusion in 21/246 brain regions, most dominant in thalamus, caudate nucleus, and anterior cingulate cortex, fitting to the topology of the 4RT disease spectrum. However, single region hypoperfusion was not specific regarding the discrimination of patients with 4RTs against patients with other neurodegenerative diseases. In contrast, perfusion pattern expression showed promise for discrimination of patients with 4RTs from other neurodegenerative diseases (AUC: 0.850). Discrimination by the combined perfusion-tau pattern expression (AUC: 0.903) exceeded that of the sole tau pattern expression (AUC: 0.864) and the discriminatory power of the combined perfusion-tau pattern expression was replicated in the external dataset (AUC: 0.917). Perfusion but not tau pattern expression was associated with PSP rating scale (R = 0.402; p = 0.0012) and activities of daily living (R =  − 0.431; p = 0.0005). CONCLUSION: [(18)F]PI-2620 perfusion imaging mirrors known topology of regional hypoperfusion in 4RTs. Single region hypoperfusion is not specific for 4RTs, but perfusion pattern expression may provide an additive value for the discrimination of 4RTs from other neurodegenerative diseases and correlates closer with clinical severity than tau pattern expression. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-022-05964-w.
format Online
Article
Text
id pubmed-9816230
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-98162302023-01-07 Additive value of [(18)F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome Katzdobler, Sabrina Nitschmann, Alexander Barthel, Henryk Bischof, Gerard Beyer, Leonie Marek, Ken Song, Mengmeng Wagemann, Olivia Palleis, Carla Weidinger, Endy Nack, Anne Fietzek, Urban Kurz, Carolin Häckert, Jan Stapf, Theresa Ferschmann, Christian Scheifele, Maximilian Eckenweber, Florian Biechele, Gloria Franzmeier, Nicolai Dewenter, Anna Schönecker, Sonja Saur, Dorothee Schroeter, Matthias L. Rumpf, Jost-Julian Rullmann, Michael Schildan, Andreas Patt, Marianne Stephens, Andrew W. van Eimeren, Thilo Neumaier, Bernd Drzezga, Alexander Danek, Adrian Classen, Joseph Bürger, Katharina Janowitz, Daniel Rauchmann, Boris-Stephan Stöcklein, Sophia Perneczky, Robert Schöberl, Florian Zwergal, Andreas Höglinger, Günter U. Bartenstein, Peter Villemagne, Victor Seibyl, John Sabri, Osama Levin, Johannes Brendel, Matthias Eur J Nucl Med Mol Imaging Original Article PURPOSE: Early after [(18)F]PI-2620 PET tracer administration, perfusion imaging has potential for regional assessment of neuronal injury in neurodegenerative diseases. This is while standard late-phase [(18)F]PI-2620 tau-PET is able to discriminate the 4-repeat tauopathies progressive supranuclear palsy and corticobasal syndrome (4RTs) from disease controls and healthy controls. Here, we investigated whether early-phase [(18)F]PI-2620 PET has an additive value for biomarker based evaluation of 4RTs. METHODS: Seventy-eight patients with 4RTs (71 ± 7 years, 39 female), 79 patients with other neurodegenerative diseases (67 ± 12 years, 35 female) and twelve age-matched controls (69 ± 8 years, 8 female) underwent dynamic (0–60 min) [(18)F]PI-2620 PET imaging. Regional perfusion (0.5–2.5 min p.i.) and tau load (20–40 min p.i.) were measured in 246 predefined brain regions [standardized-uptake-value ratios (SUVr), cerebellar reference]. Regional SUVr were compared between 4RTs and controls by an ANOVA including false-discovery-rate (FDR, p < 0.01) correction. Hypoperfusion in resulting 4RT target regions was evaluated at the patient level in all patients (mean value − 2SD threshold). Additionally, perfusion and tau pattern expression levels were explored regarding their potential discriminatory value of 4RTs against other neurodegenerative disorders, including validation in an independent external dataset (n = 37), and correlated with clinical severity in 4RTs (PSP rating scale, MoCA, activities of daily living). RESULTS: Patients with 4RTs had significant hypoperfusion in 21/246 brain regions, most dominant in thalamus, caudate nucleus, and anterior cingulate cortex, fitting to the topology of the 4RT disease spectrum. However, single region hypoperfusion was not specific regarding the discrimination of patients with 4RTs against patients with other neurodegenerative diseases. In contrast, perfusion pattern expression showed promise for discrimination of patients with 4RTs from other neurodegenerative diseases (AUC: 0.850). Discrimination by the combined perfusion-tau pattern expression (AUC: 0.903) exceeded that of the sole tau pattern expression (AUC: 0.864) and the discriminatory power of the combined perfusion-tau pattern expression was replicated in the external dataset (AUC: 0.917). Perfusion but not tau pattern expression was associated with PSP rating scale (R = 0.402; p = 0.0012) and activities of daily living (R =  − 0.431; p = 0.0005). CONCLUSION: [(18)F]PI-2620 perfusion imaging mirrors known topology of regional hypoperfusion in 4RTs. Single region hypoperfusion is not specific for 4RTs, but perfusion pattern expression may provide an additive value for the discrimination of 4RTs from other neurodegenerative diseases and correlates closer with clinical severity than tau pattern expression. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-022-05964-w. Springer Berlin Heidelberg 2022-09-14 2023 /pmc/articles/PMC9816230/ /pubmed/36102964 http://dx.doi.org/10.1007/s00259-022-05964-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Katzdobler, Sabrina
Nitschmann, Alexander
Barthel, Henryk
Bischof, Gerard
Beyer, Leonie
Marek, Ken
Song, Mengmeng
Wagemann, Olivia
Palleis, Carla
Weidinger, Endy
Nack, Anne
Fietzek, Urban
Kurz, Carolin
Häckert, Jan
Stapf, Theresa
Ferschmann, Christian
Scheifele, Maximilian
Eckenweber, Florian
Biechele, Gloria
Franzmeier, Nicolai
Dewenter, Anna
Schönecker, Sonja
Saur, Dorothee
Schroeter, Matthias L.
Rumpf, Jost-Julian
Rullmann, Michael
Schildan, Andreas
Patt, Marianne
Stephens, Andrew W.
van Eimeren, Thilo
Neumaier, Bernd
Drzezga, Alexander
Danek, Adrian
Classen, Joseph
Bürger, Katharina
Janowitz, Daniel
Rauchmann, Boris-Stephan
Stöcklein, Sophia
Perneczky, Robert
Schöberl, Florian
Zwergal, Andreas
Höglinger, Günter U.
Bartenstein, Peter
Villemagne, Victor
Seibyl, John
Sabri, Osama
Levin, Johannes
Brendel, Matthias
Additive value of [(18)F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome
title Additive value of [(18)F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome
title_full Additive value of [(18)F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome
title_fullStr Additive value of [(18)F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome
title_full_unstemmed Additive value of [(18)F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome
title_short Additive value of [(18)F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome
title_sort additive value of [(18)f]pi-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816230/
https://www.ncbi.nlm.nih.gov/pubmed/36102964
http://dx.doi.org/10.1007/s00259-022-05964-w
work_keys_str_mv AT katzdoblersabrina additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT nitschmannalexander additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT barthelhenryk additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT bischofgerard additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT beyerleonie additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT marekken additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT songmengmeng additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT wagemannolivia additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT palleiscarla additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT weidingerendy additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT nackanne additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT fietzekurban additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT kurzcarolin additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT hackertjan additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT stapftheresa additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT ferschmannchristian additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT scheifelemaximilian additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT eckenweberflorian additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT biechelegloria additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT franzmeiernicolai additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT dewenteranna additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT schoneckersonja additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT saurdorothee additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT schroetermatthiasl additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT rumpfjostjulian additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT rullmannmichael additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT schildanandreas additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT pattmarianne additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT stephensandreww additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT vaneimerenthilo additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT neumaierbernd additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT drzezgaalexander additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT danekadrian additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT classenjoseph additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT burgerkatharina additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT janowitzdaniel additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT rauchmannborisstephan additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT stockleinsophia additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT perneczkyrobert additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT schoberlflorian additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT zwergalandreas additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT hoglingergunteru additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT bartensteinpeter additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT villemagnevictor additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT seibyljohn additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT sabriosama additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT levinjohannes additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT brendelmatthias additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome
AT additivevalueof18fpi2620perfusionimaginginprogressivesupranuclearpalsyandcorticobasalsyndrome